Carglumic Acid
This drug acts as a structural analog of N-acetylglutamate, activating the enzyme carbamoyl phosphate synthetase 1, which is essential for the urea cycle. It is used to treat hyperammonemia caused by N-acetylglutamate synthase deficiency, a rare metabolic disorder. Treatment allows the body to properly eliminate nitrogen waste, preventing toxic ammonia buildup.
Peso Molecular
190,1500 g/mol
LogP
-2,40
TPSA
130,00 Ų
Regra dos 5 de Lipinski
Aprovado
Mecanismo de Ação
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Estrutura 2D
Cite this structure
Embed this structure
SMILES
NC(=O)N[C@@H](CCC(=O)O)C(=O)O
InChI
InChI=1S/C6H10N2O5/c7-6(13)8-3(5(11)12)1-2-4(9)10/h3H,1-2H2,(H,9,10)(H,11,12)(H3,7,8,13)/t3-/m0/s1
Molecular Formula
C6H10N2O5
HBD / HBA
4 / 5
Ligações Rotacionáveis
5
Átomos Pesados
13
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
This drug acts as a structural analog of N-acetylglutamate, activating the enzyme carbamoyl phosphate synthetase 1, which is essential for the urea cycle. It is used to treat hyperammonemia caused by N-acetylglutamate synthase deficiency, a rare metabolic disorder. Treatment allows the body to properly eliminate nitrogen waste, preventing toxic ammonia buildup.
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Yes, Carglumic Acid is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201780. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 121396. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="carglumic-acid"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/carglumic-acid/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/carglumic-acid/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/carglumic-acid/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="carglumic-acid"></drugfyi-drug>